ISSN: 2167-7700
Georg Weber
Pancreatic cancer is one of the greatest lethal malignancies and is associated with a poor prognosis. Surgery is considered the only potential curative treatment for pancreatic cancer, shadowed by adjuvant chemotherapy, but surgery is earmarked for the minority of patients with non-metastatic resectable tumors. In the future, neoadjuvant treatment strategies grounded on molecular testing of tumor biopsies may increase the amount of patients flattering eligible for surgery. In the context of nonmetastatic disease, patients with resectable or borderline resectable pancreatic carcinoma might advantage from neoadjuvant chemo- or chemoradiotherapy shadowed by surgery.